Exclusive Summary

• • Global GLP‑1 demand is surging with persistent shortages, creating a natural entry window for new suppliers across many countries. • Major guidelines (ADA/EASD) strongly recommend GLP‑1 for T2D with ASCVD/obesity (not on WHO EML yet), giving clear clinical use-cases. • Aside from limited liraglutide copies in a few markets, there is virtually no scaled GLP‑1 generic supply, leaving a competitive white space. • A value story of stable supply + competitive pricing (≈30–60% vs originators) + low injection volume (1 mg/0.5 mL) can unlock fast distribution and access in underpenetrated markets.